Clinical Research Directory
Browse clinical research sites, groups, and studies.
Combined Tranexamic Acid Use in Total Hip Replacement Surgery
Sponsor: St. Anne's University Hospital Brno, Czech Republic
Summary
This prospective study evaluates whether combined intravenous and topical administration of tranexamic acid (TXA) can safely reduce blood loss in patients undergoing primary total hip replacement surgery. Tranexamic acid is commonly used during orthopedic surgery to decrease bleeding and reduce the need for blood transfusions. Participants undergoing elective primary total hip arthroplasty are assigned to receive either intravenous TXA alone or a combination of intravenous and topical TXA applied directly around the hip joint during surgery. The study compares postoperative blood loss, changes in hemoglobin levels, transfusion requirements, length of hospital stay, and postoperative complications between the treatment groups. The study also uses rotational thromboelastometry (ROTEM), a specialized blood coagulation monitoring method, to evaluate whether combined TXA administration affects blood clotting or increases the risk of thromboembolic complications such as deep vein thrombosis or pulmonary embolism.
Official title: Combined Intravenous and Topical Tranexamic Acid in Total Hip Arthroplasty: A Prospective Comparative Study With Rotational Thromboelastometry Monitoring
Key Details
Gender
All
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
58
Start Date
2024-06-01
Completion Date
2025-07-31
Last Updated
2026-05-28
Healthy Volunteers
No
Conditions
Interventions
Intravenous Tranexamic Acid
Participants receive a single 1 g intravenous dose of tranexamic acid administered before surgical incision during primary total hip arthroplasty without additional topical application.
Combined Intravenous and Intraarticular Tranexamic Acid
Participants receive tranexamic acid administered through two routes during primary total hip arthroplasty. A 1 g intravenous dose is administered before surgical incision, followed by an additional 2 g topical dose applied locally around the hip prosthesis during wound closure after implantation of the components and achievement of hemostasis.
Locations (1)
First Department of Orthopaedic Surgery, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Brno, Czechia
Brno, Czechia, Czechia